Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Gains from Sales and Divestitures (2021 - 2024)

Historic Gains from Sales and Divestitures for Aligos Therapeutics (ALGS) over the last 3 years, with Q3 2024 value amounting to $4874.0.

  • Aligos Therapeutics' Gains from Sales and Divestitures changed N/A to $4874.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $4874.0, marking a year-over-year change of. This contributed to the annual value of $89054.0 for FY2022, which is 7211.46% down from last year.
  • According to the latest figures from Q3 2024, Aligos Therapeutics' Gains from Sales and Divestitures is $4874.0.
  • Over the past 5 years, Aligos Therapeutics' Gains from Sales and Divestitures peaked at $319357.0 during Q4 2021, and registered a low of $2490.0 during Q1 2024.
  • For the 3-year period, Aligos Therapeutics' Gains from Sales and Divestitures averaged around $109125.2, with its median value being $89054.0 (2022).
  • Examining YoY changes over the last 5 years, Aligos Therapeutics' Gains from Sales and Divestitures showed a top increase of 3522.83% in 2022 and a maximum decrease of 7211.46% in 2022.
  • Over the past 3 years, Aligos Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $319357.0 in 2021, then plummeted by 72.11% to $89054.0 in 2022, then crashed by 94.53% to $4874.0 in 2024.
  • Its Gains from Sales and Divestitures was $4874.0 in Q3 2024, compared to $2490.0 in Q2 2024 and $2490.0 in Q1 2024.